This effort has culminated in a substantial compilation of clinical case studies and a solid research foundation.20,21 The present study used the Al18F-NOTA-HER2-BCH agent to evaluate its safety, feasibility, biodistribution, and efficacy in targeting tumors within breast cancer patients. Here, ERBB2 is linked to choreatic disease.